Updating results

99 results for dyspepsia

Sort: Relevance | Date

Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

Summary of the evidence on tadalafil for lower urinary tract symptoms secondary to benign prostate hyperplasia..

Evidence summary Published May 2013 Last updated October 2013

In people who experience symptoms of gastro-oesophageal reflux disease (GORD) or symptoms suggestive of GORD, what patient characteristics, risk factors and predictors indicate when endoscopy is needed to exclude Barrett's oesophagus?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published November 2019

What is the effectiveness of laparoscopic fundoplication compared with medical management in people with GORD that does not respond to optimal proton pump inhibitor (PPI) treatment?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published November 2019

Laparoscopic fundoplication compared with medical management:- What is the effectiveness of laparoscopic fundoplication compared with medical management in people with GORD that does not respond to optimal proton pump inhibitor (PPI) treatment?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published June 2015

What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published November 2019

What is the clinical effectiveness of double-dose PPIs in people with severe erosive reflux disease (Los Angeles classification grade C/D or Savary–Miller grade 3/4): to reduce severe oesophagitis to control symptoms as maintenance therapy?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published November 2019

Other specialist management:- What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

details Comes from guidance Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Number CG184 Date

Research recommendation Published June 2015

Infliximab for acute exacerbations of ulcerative colitis (TA163)

Evidence-based recommendations on infliximab (Remicade) for acute exacerbations of ulcerative colitis in adults

Technology appraisal guidance Published December 2008

Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making

Evidence summary Published March 2017

Dyspepsia: Management of dyspepsia in adults in primary care (CG17)

This guidance has been updated and replaced by NICE guideline CG184.

Clinical guideline Published August 2004

Chest pain of recent onset: assessment and diagnosis (CG95)

This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.

Clinical guideline Published March 2010 Last updated November 2016

Autoimmune haemolytic anaemia: rituximab (ESUOM39)

Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

Evidence summary Published February 2015

Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) (ESUOM11)

Summary of the evidence on vaginal misoprostol (after oral mifepristone) for induction labour in late intrauterine fetal death (IUFD)..

Evidence summary Published April 2013

Multimorbidity

Everything NICE has said on optimising care for people with 2 or more long-term health conditions in an interactive flowchart

NICE Pathway Published September 2016 Last updated July 2017

Stretta System for gastro-oesophageal reflux disease (MIB74)

Advice on the use of Stretta System for gastro-oesophageal reflux disease (GORD)

Medtech innovation briefing Published July 2016

Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

Summary of the evidence on glycopyrronium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published January 2013

Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published July 2015

Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)

Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making

Evidence summary Published October 2015

Dementia. Enteral (tube) feeding for people living with severe dementia (patient decision aid)

there are treatable reasons for the person's loss of appetite (such as indigestion, constipation or a sore mouth) these should be...

Published June 2018 Last updated June 2018

Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for the treatment of chronic hepatitis B

Technology appraisal guidance Published February 2006

Medicines optimisation

Everything NICE has said on shared decision-making and processes to optimise medicines and support adherence in an interactive flowchart

NICE Pathway Published March 2015 Last updated October 2019

Patisiran for treating hereditary transthyretin amyloidosis (HST10)

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Highly specialised technologies guidance Published August 2019

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism

Technology appraisal guidance Published July 2012

Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

Summary of the evidence on adjuvant bisphosphonates for preventing recurrence or improving survival in people with early breast cancer

Evidence summary Published July 2017

The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia (TA7)

This guidance has been replaced by NICE guideline CG17. [Replaced by NICE guideline CG184]

Technology appraisal guidance Published July 2000

Hypersexuality: fluoxetine (ESUOM46)

Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making

Evidence summary Published July 2015

Coeliac disease: recognition, assessment and management (NG20)

This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.

NICE guideline Published September 2015

Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)

Technology appraisal guidance Published February 2011 Last updated August 2013

Bisphosphonates for treating osteoporosis. Bisphosphonates for treating osteoporosis Patient decision aid

bisphosphonate treatment? The most common side effects include: : heartburn and indigestion : pain or stiffness in your muscles, joints...

Published October 2017 Last updated August 2019 Last updated August 2019

Obesity: identification, assessment and management (CG189)

This guideline covers identifying, assessing and managing obesity in children (aged 2 years and over), young people and adults. It aims to improve the use of bariatric surgery and very-low-calorie diets to help people who are obese to reduce their weight.

Clinical guideline Published November 2014

Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

Summary of the evidence on long-term azithromycin for treating non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published November 2014

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism

Technology appraisal guidance Published June 2013

Coeliac disease

Everything NICE has said on recognising, diagnosing and managing coeliac disease in an interactive flowchart

NICE Pathway Published October 2012 Last updated October 2017

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)

Technology appraisal guidance Published March 2015

Smokeless tobacco: South Asian communities (PH39)

This guideline covers people living in England with ancestral links to Bangladesh, India, Nepal, Pakistan or Sri Lanka who use traditional South Asian varieties of smokeless tobacco. The aim is to help them stop using tobacco that is placed in the mouth or nose (but not burned). It does not include oral snuff products that are sucked.

Public health guideline Published September 2012

Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

Evidence-based recommendations on olaparib (Lynparza)

Technology appraisal guidance Published January 2016

Mirabegron for treating symptoms of overactive bladder (TA290)

Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder

Technology appraisal guidance Published June 2013

Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (TA293)

Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)

Technology appraisal guidance Published July 2013 Last updated October 2018

Erectile dysfunction: avanafil (ESNM45)

Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

Evidence summary Published August 2014

Type 2 diabetes: dulaglutide (ESNM59)

Summary of the evidence on dulaglutide for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published June 2015

Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis (MS/RRMS)

Technology appraisal guidance Published August 2014

Migalastat for treating Fabry disease (HST4)

Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16

Highly specialised technologies guidance Published February 2017

Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

Summary of the evidence on liraglutide for managing obesity and overweight with risk factors in adults to inform local NHS planning and decision-making

Evidence summary Published June 2017

Cardiovascular disease. Patient decision aid

bleed  allergic reactions  headache  nausea, constipation, wind, indigestion, diarrhoea. Other side effects have been reported with...

Published November 2014 Last updated November 2014

Research recommendations

be conducted to exclude a diagnosis of functional dyspepsia in people with uninvestigated dyspepsia that does not respond...

Published April 2016 Last updated April 2016

Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays) (DG15)

Evidence-based recommendations on high-sensitivity troponin tests for the early rule-out of acute myocardial infarction (AMI)

Diagnostics guidance Published October 2014

NICE updates advice on treatment of digestive disorders

Updated guidance from NICE on dyspepsia includes new advice on proton pump inhibitor therapy and the referral criteria for specialist services.

News Published August 2014 Last updated August 2014